Hancock Whitney Corp Has $14.28 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Hancock Whitney Corp reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,323 shares of the medical research company’s stock after selling 132 shares during the quarter. Hancock Whitney Corp’s holdings in Amgen were worth $14,281,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in Amgen during the 3rd quarter valued at about $25,000. Hershey Financial Advisers LLC acquired a new stake in shares of Amgen during the second quarter worth approximately $30,000. nVerses Capital LLC bought a new position in shares of Amgen in the second quarter valued at approximately $31,000. Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter worth approximately $33,000. Finally, Matrix Trust Co bought a new stake in Amgen during the 3rd quarter worth approximately $36,000. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and raised their price objective for the stock from $320.00 to $333.00 in a research note on Monday, October 14th. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Finally, Robert W. Baird restated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a report on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $333.57.

Amgen Stock Down 0.5 %

Shares of AMGN opened at $293.00 on Monday. The firm’s 50-day simple moving average is $316.52 and its 200 day simple moving average is $318.18. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market cap of $157.50 billion, a P/E ratio of 37.71, a price-to-earnings-growth ratio of 2.63 and a beta of 0.60. Amgen Inc. has a 52 week low of $260.68 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the company earned $4.96 earnings per share. On average, analysts forecast that Amgen Inc. will post 19.52 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 3.07%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.